LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Kodu・Aktsiate loetelu・Cogent Biosciences Inc

Cogent Biosciences Inc

Suletud

33.54 -0.86

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

33.39

Max

35.09

Põhinäitajad
By Trading Economics
Sissetulek	-7.4M -81M
Aktsiakasum	-0.5
Kasumimarginaal	-1,582.642
Töötajad	205
EBITDA	-11M -83M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+20.13% upside

Turustatistika
By TradingEconomics
Turukapital	2.5B 4.6B
Eelmine avamishind	34.4
Eelmine sulgemishind	33.54

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

4.88 / 5.87 Toetus ja vastupanu

Cogent Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. nov 2025, 17:45 UTC

Tulu

Suurimad hinnamuutused turgudel

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14. nov 2025, 17:31 UTC

Tulu

Suurimad hinnamuutused turgudel

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

14. nov 2025, 16:15 UTC

Suurimad hinnamuutused turgudel

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

14. nov 2025, 23:56 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14. nov 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14. nov 2025, 22:35 UTC

Tulu

Omandamised, ülevõtmised, äriostud

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14. nov 2025, 22:32 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14. nov 2025, 22:29 UTC

Tulu

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14. nov 2025, 22:00 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14. nov 2025, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

14. nov 2025, 21:18 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14. nov 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14. nov 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14. nov 2025, 20:17 UTC

Omandamised, ülevõtmised, äriostud

Several State Attorneys General Oppose Railroad Merger -- WSJ

14. nov 2025, 19:29 UTC

Market Talk

Tulu

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14. nov 2025, 18:44 UTC

Market Talk

Tulu

Disney's Growth Now Hinges More on ESPN -- Market Talk

14. nov 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14. nov 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14. nov 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14. nov 2025, 17:20 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

14. nov 2025, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

14. nov 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14. nov 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14. nov 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

14. nov 2025, 16:38 UTC

Market Talk

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

14. nov 2025, 16:30 UTC

Omandamised, ülevõtmised, äriostud

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

14. nov 2025, 16:28 UTC

Market Talk

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

14. nov 2025, 15:59 UTC

Market Talk

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

14. nov 2025, 15:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. nov 2025, 15:06 UTC

Market Talk

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Cogent Biosciences Inc Prognoos

Hinnasiht

By TipRanks

20.13% tõus

12 kuu keskmine prognoos

Keskmine 40.64 USD 20.13%

Kõrge 65 USD

Madal 20 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Cogent Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Cogent Biosciences Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

4.88 / 5.87Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.